## CITATION REPORT List of articles citing

Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019

DOI: 10.1001/jamapediatrics.2020.2422 JAMA Pediatrics, 2020, 174, e202422.

Source: https://exaly.com/paper-pdf/76818202/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. <i>Italian Journal of Pediatrics</i> , <b>2020</b> , 46, 139	3.2	35
31	A Narrative Review of Emerging Therapeutics for COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2020</b> , 4, 745-758	3.1	5
30	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , <b>2020</b> , 33, 177-19	8 <sup>9.8</sup>	О
29	Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 194, 113806	3.5	6
28	Compassionate use of remdesivir in children with COVID-19. <i>European Journal of Pediatrics</i> , <b>2021</b> , 180, 1317-1322	4.1	16
27	Characterising and managing paediatric SARSCoV-2 infection: Learning about the virus in a global classroom. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>2021</b> , 110, 409-422	3.1	2
26	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 102, 275-281	10.5	7
25	Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 602880	5.6	О
24	Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 1092-1	168	4
23	Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 1116-1124	6.1	8
22	Rapid Implementation of Model-Based Dosing Recommendations During the Coronavirus Disease 2019 Pandemic. <i>JAMA Pediatrics</i> , <b>2021</b> , 175, 432-433	8.3	
21	Rapid Implementation of Model-Based Dosing Recommendations During the Coronavirus Disease 2019 Pandemic-Reply. <i>JAMA Pediatrics</i> , <b>2021</b> , 175, 433	8.3	
20	Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use. <i>Pediatrics</i> , <b>2021</b> , 147,	7.4	
19	Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges. <i>Biochemical Pharmacology</i> , <b>2021</b> , 189, 114468	6	3
18	Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e853-e864	2	5
17	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
16	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	4

## **CITATION REPORT**

Healthy Volunteers.

Challenges in predicting the pharmacokinetics of drugs in premature and mature newborns: 15 example with piperacillin and tazobactam. 2022, 437-456 Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized 1.8 14 Hydroxychloroguine for Pulmonary Delivery to COVID-19 Patients. Drug Research, 2021, 71, 250-256 Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Frontiers in 8 5.6 13 Pharmacology, **2020**, 11, 590598 Tissue Level Profiling of SARS-CoV-2 antivirals in mice to predict their effects: comparing 12 Remdesivir active metabolite GS-441 524 vs. the clinically failed Hydroxychloroquine. Challenges and opportunities for improving access to approved neonatal drugs and devices.. 11 Ο 3.1 Journal of Perinatology, 2022, COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines.. Children, 2.8 8 10 2022, 9, SARS-CoV-2 Associated Respiratory Failure in a Preterm Infant and the Outcome after Remdesivir 9 1 3.4 Treatment.. Pediatric Infectious Disease Journal, 2022, COVID-19 in Children: Update on Diagnosis and Management.. Seminars in Respiratory and Critical 3.9 Care Medicine, 2021, 42, 737-746 Severe COVID-19 Complicated by Cerebral Venous Thrombosis in a Newborn Successfully Treated with Remdesivir, Glucocorticoids, and Hyperimmune Plasma.. International Journal of Environmental 4.6 2 Research and Public Health, 2021, 18, 6 datasheet1.pdf. 2020, image1.jpeg. 2020, 5 table1.xlsx. 2020, table2.xlsx. 2020, 3 Predicting the Correct Dose in Children: Role of Computational PBPK Modeling Tools.

Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in

 $\circ$